Author

J. G. Park

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Kim· 2 shared J. H. Kim· 2 shared J. Y. Cho· 2 shared N. Parameswaran· 2 shared S. Kim· 2 shared W. S. Yang· 2 shared Y.-S. Yi· 2 shared B. C. Yoo· 1 shared

Activity by Year

2018-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Kim

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MyD88-Syk axis is a critical determinant for inflammatory response in macrophages

Y.-S. Yi, J. H. Kim, W. S. Yang, E. Kim, D. Jeong, J. G. Park, N. Aziz, S. Kim, N. Parameswaran, J. Y. Cho

This study shows that the MyD88-Syk axis drives inflammatory responses in macrophages by promoting ROS/RNS generation and phagocytic activity through Src, F-actin, and Rac1.

bioRxiv · Nov 15, 2019 · PreprintImmunology

Metastatic function of METTL18 in breast cancer via actin methylation and Src

H. G. Kim, J. H. Kim, W. S. Yang, J. G. Park, Y. G. Lee, E. Kim, Y. H. Hong, M. Jo, C. Y. Lee, S. H. Kim, N. Y. Sung, Y.-S. Yi, Z. A. Ratan, S. Kim, B. C. Yoo, , J. Y. Cho

This study identifies METTL18 as an actin histidine methyltransferase that enhances breast cancer metastasis by promoting actin polymerization and Src activation.

bioRxiv · Nov 5, 2019 · PreprintCancer Biology

Multifunctional CRISPR/Cas9 with engineered immunosilenced human T cell epitopes

S. R. Ferdosi, R. Ewaisha, F. Moghadam, S. Krishna, J. G. Park, M. R. Ebrahimkhani, S. Kiani, K. S. Anderson

This study shows that Cas9 can be modified to reduce immunogenicity while maintaining its function.

bioRxiv · Jul 2, 2018Immunology